SCF API Equivalent: NO-API-Θ2

PCR Mode: Curative Core

Biological Target Domain

Mitochondrial bioenergetic collapse
Neuroimmune dysregulation
Autonomic governance instability
Neuroendocrine stress-axis disruption

The Stabilization Engine is the central therapeutic leverage point of the SCF-PCR platform.

Once the Intercept Engine establishes regulatory stability, this phase restores cellular energy capacity and resolves immune misidentification that drives progressive neurodegeneration.

1. SYSTEM PATHOGENESIS TARGET

Mitochondrial Energy Collapse

ETC dysfunction
        ↓
ATP depletion
        ↓
Synaptic failure
        ↓
Neurodegeneration

Microglial Immune Misidentification

Metabolic stress
        ↓
Inflammasome activation
        ↓
Microglial pruning of synapses

Autonomic Governance Failure

ANS dysregulation
        ↓
cerebral perfusion instability
        ↓
metabolic mismatch

HPA-Axis Stress Lock

chronic cortisol dysregulation
        ↓
immune intolerance
        ↓
neuroinflammation persistence

2. FDA DRUG MAPPING

A. Mitochondrial Bioenergetic Restoration

Justification

Neurons require continuous ATP production.

NAD⁺ depletion and ETC dysfunction are consistently observed in Alzheimer’s disease.

These compounds restore:

• oxidative phosphorylation efficiency
• mitochondrial redox balance
• neuronal energy stability

B. Mitochondrial Biogenesis Activation

Justification

Metformin activates AMPK–PGC-1α pathways, promoting mitochondrial biogenesis and improving metabolic efficiency in neuronal tissue.

This mechanism supports:

• increased mitochondrial population
• improved oxidative metabolism
• reduced oxidative stress

C. Mitophagy Restoration

Justification

Mitophagy failure allows dysfunctional mitochondria to accumulate, producing ROS and metabolic collapse.

Mitophagy activation restores mitochondrial quality control.

D. Neuroimmune Tolerance Restoration

Justification

Microglial activation leads to synaptic loss through inflammatory pruning.

These agents reduce:

• inflammasome signaling
• microglial overactivation
• cytokine amplification loops

E. Autonomic Nervous System Stabilization

Justification

Autonomic instability produces:

• impaired cerebral perfusion
• metabolic mismatch
• inflammatory amplification

ANS stabilization restores brain perfusion and autonomic-immune coupling.

F. Neuroendocrine Stabilization

Justification

HPA-axis dysregulation contributes to chronic inflammation and metabolic stress.

Stabilizing cortisol rhythms restores immune tolerance signaling.

3. DOSE-TIER ARCHITECTURE (SCF MODEL)

The stabilization phase uses progressive metabolic activation tiers.

Each escalation step must occur only when energy markers demonstrate recovery.

4. ESCALATION LOGIC

Escalation permitted when

ATP markers increasing
lactate normalized
HRV stable
inflammatory markers decreasing

Escalation blocked when

ROS markers rising
immune activation spike
autonomic instability
persistent fatigue escalation

5. BIOMARKER THRESHOLDS

6. STOP / HOLD RULES

Stabilization phase is paused if:

ROS spike detected
cytokine flare
HRV collapse
sleep architecture deterioration

These indicate system destabilization, requiring return to Intercept Engine stabilization.

7. STABILIZATION ENGINE OUTPUT

Successful completion of the stabilization phase produces:

restored mitochondrial energy production
resolved neuroinflammation
stable autonomic governance
balanced neuroendocrine signaling

These conditions create the biological readiness state for structural neural repair in the Restoration Engine.